Investment Analysts’ Weekly Ratings Updates for Cytokinetics (CYTK)

Posted by Brian Himes on Aug 10th, 2026

Several brokerages have updated their recommendations and price targets on shares of Cytokinetics (NASDAQ: CYTK) in the last few weeks:

8/8/2026 – Cytokinetics was downgraded by Wall Street Zen from “hold” to “sell”.
8/7/2026 – Cytokinetics had its price target lowered by Royal Bank Of Canada from $117.00 to $112.00. They now have an “outperform” rating on the stock.
8/7/2026 – Cytokinetics had its “market outperform” rating reaffirmed by Citigroup Inc..
8/7/2026 – Cytokinetics had its price target raised by Citizens Jmp from $105.00 to $110.00. They now have a “market outperform” rating on the stock.
8/7/2026 – Cytokinetics had its price target raised by Needham & Company LLC from $102.00 to $112.00. They now have a “buy” rating on the stock.
7/17/2026 – Cytokinetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
7/7/2026 – Cytokinetics had its price target lowered by Royal Bank Of Canada from $119.00 to $117.00. They now have an “outperform” rating on the stock.
6/29/2026 – Cytokinetics was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $115.00 price target on the stock, up from $69.00.
6/24/2026 – Cytokinetics had its price target raised by Mizuho from $100.00 to $118.00. They now have an “outperform” rating on the stock.
6/17/2026 – Cytokinetics had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $119.00 price target on the stock.
6/17/2026 – Cytokinetics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $102.00 price target on the stock.

Insiders Place Their Bets

In other news, EVP Fady Ibraham Malik sold 3,500 shares of the stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $80.59, for a total transaction of $282,065.00. Following the completion of the transaction, the executive vice president directly owned 153,902 shares of the company’s stock, valued at approximately $12,402,962.18. This represents a 2.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $79.88, for a total value of $1,118,320.00. Following the completion of the sale, the executive vice president directly owned 58,555 shares of the company’s stock, valued at $4,677,373.40. This represents a 19.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 115,179 shares of company stock worth $9,126,054 over the last quarter. 2.60% of the stock is owned by company insiders.

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

Investment Analysts’ Weekly Ratings Updates for Cytokinetics (CYTK)

Insiders Place Their Bets

See Also

You might be interested in: